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Abstract
Post-ischemic reperfusion may result in reactive oxygen species (ROS) generation, reduced availability of nitric oxide
(NO), Ca2+overload, prolonged opening of mitochondrial permeability transition pore, and other processes con-
tributing to cell death, myocardial infarction, stunning, and arrhythmias. With the discovery of the preconditioning
and postconditioning phenomena, reperfusion injury has been appreciated as a reality from which protection
is feasible, especially with postconditioning, which is under the control of physicians. Potentially cooperative pro-
tective signaling cascades are recruited by both pre- and postconditioning. In these pathways, phosphorylative=
dephosphorylative processes are widely represented. However, cardioprotective modalities of signal transduction
also include redox signaling by ROS, S-nitrosylation byNO and derivative, S-sulfhydration by hydrogen sulfide, and
O-linked glycosylation with beta-N-acetylglucosamine. All these modalities can interact and regulate an entire
pathway, thus influencing each other. For instance, enzymes can be phosphorylated and=or nitrosylated in specific
and=or different site(s) with consequent increase or decrease of their specific activity. The cardioprotective signaling
pathways are thought to converge on mitochondria, and various mitochondrial proteins have been identified as
targets of these post-transitional modifications in both pre- and postconditioning. Antioxid. Redox Signal. 14, 833–850.
Introduction
Acute coronary artery diseases are the leading causeof mortality and morbidity in Western countries. Cardio-
logical practice has changed rapidly over the last few years,
progressing from thrombolysis to direct coronary intervention
and stenting to rapidly restore myocardial blood flow. It is
generally accepted that whenever possible a short door-to-
balloon time limits infarct size, ventricular dysfunction, and
major cardiac adverse events (MACE), and, consequently,
improves prognosis (68, 109, 120, 202). Therefore, it is no doubt
that early reperfusion is the ‘‘gold standard’’ therapy for acute
myocardial infarction. In fact, these strategies have had amajor
impact on improving outcomes. However, we have also come
to understand that reperfusion itself is, paradoxically, an im-
portant cause of organ damage (68, 109, 202). Starting almost
immediately after the restoration of blood flow, a cascade of
adverse events (see below) triggers a vicious cycle leading to
additional injury and cell death. Local and more widespread
inflammatory responses will concur to increase the extent of
infarction in otherwise viable tissue. This acceleration of dam-
ages after reperfusion led to the concept of myocardial reperfu-
sion injury (3, 21, 68, 109, 156, 177, 202).
Myocardial Reperfusion Injury Is Due
to Complex Mechanisms
Reperfusion injury is due to mechanisms involving me-
chanical, extracellular, and intracellular processes. The patho-
genesis of reperfusion injury has been reviewed elsewhere (21,
53, 151, 156, 202, 207) and is beyond the aim of the present
review. However, a short description of the principal events of
the processes involved in reperfusion injury may be useful for
the reader. Schematically, acute reperfusion injury can be due to
the following interconnected key mechanisms: a) reactive oxy-
gen and nitrogen species (ROS=RNS) generation; b) reduced
availability of nitric oxide (NO); c) Ca2þoverload; and d) mito-
chondrial permeability transition pore (mPTP) opening (Fig. 1).
These mechanisms may lead to cell death and to the activa-
tion of the NFkB and other transcription factors, which, in turn,
lead to the augmented expression of molecules of cellular ad-
hesion, leukocyte infiltration, and no-reflow phenomenon, which
exacerbate tissue injury (see reviews 137, 177, 183, 201, 202, 207).
Reactive oxygen and nitrogen species generation
Reactive oxygen species (ROS) is a collective name for a
group of oxygen-containing species such as superoxide anion
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radical (O2
), hydrogen peroxide (H2O2), and hydroxyl
radical (OH). Reactive nitrogen species (RNS) refers to the
family of compounds derived from NO, the signaling mole-
cule synthesized from L-arginine by the nitric oxide synthases
(NOSs, i.e., neuronal, endothelial, and inducible NOS). NO
can also be converted, by oxidation or reduction, into many
chemically reactive forms including nitrogen dioxide radicals
(NO2
), peroxynitrite (ONOO-), and nitroxyl (HNO), each of
which yields distinct functional consequences (11, 12, 55, 138,
142, 164, 198). The implications of the biological balance be-
tween NO and oxidative stress have been examined in detail
in several recent reviews (12, 55, 112, 138, 164, 198).
Various deleterious processes can be the result of an im-
balance between the excess formation of ROS and=or RNS
and limited antioxidant defenses (referred to as ‘oxidative
stress’). For instance, ROS indiscriminately react with lipids,
proteins, and DNA. These are complex processes: in brief,
ROS reaction with lipids gives rise to peroxyl and alkoxyl
radicals leading to lipid peroxidation; reaction with amino
acid residue side chains of proteins form protein carbonyls,
and reaction with methionine forms methionine sulfide; re-
action with DNA may oxidize DNA bases such as 8-OhdG,
leading to mutation and DNA strand breaking (1, 12, 187, 204,
208–212). Excessive ROS=RNS production is considered del-
eterious to cell function and mitochondria, where they act as
inducers of mPTP opening (see below). Alternatively, low
levels of reactive species may act as secondary messengers,
modulating signalling pathways by covalent modification of
target molecules (referred to as ‘redox signaling’, see also
below).
Oxidative stress related to the massive generation of
ROS=RNS may play an important role in reperfusion injury
(1, 12, 187, 204, 208–212). At reperfusion, O2
 and other ROS
may strongly oxidize the cardiomyocytes already damaged
by the ischemia, thus favoring cell death (1, 2, 53, 116, 183,
184). Moreover, in reperfusion, O2
 may react with NO,
formingONOO. Therefore, ONOO, may represent a sign of
a reduced availability of NO and it may participate with O2

in myocardial injury (10-12, 52, 135, 165). In particular, high
ONOO concentrations are considered to be highly cytotoxic
(11, 12, 135, 165). Peroxynitrite cytotoxicity is also due to its
reaction with proteins (on tyrosine and thiol groups), lipids,
and DNA (11, 12, 21, 135, 159). For instance, peroxynitrite
inactivates prostacyclin synthase by tyrosine nitration, play-
ing a crucial role in the pathophysiology of the cardiovascular
system (211). The contribution of high levels of ONOO to
myocardial and vascular dysfunction during ischemia and
reperfusion, and other cardiovascular pathologies has re-
cently been reviewed (53, 135).
Although the sources of ROS and RNS within the cells are
many, in cardiomyocytes the main sources are mitochondria
(38–41,142). It has been suggested that for massive ROS re-
lease the involvement of mPTP is required. Zorov et al. (209)
‘‘triggered’’ massive ROS release in isolated cardiomyocytes
via intracellular photoactivation of tetramethylrhodamine
compounds. These triggered-ROS were associated with mi-
tochondrial depolarization, along with prolonged mPTP
opening and a consequent large burst of ROS from mito-
chondria. Thus, a positive feedback loop of ‘‘ROS-induced
ROS release’’ has been suggested (209, 210). These organelles
may also produce a large quantity of ROS from monoamine
oxidase and p66Shc activity (39–41). Even NOSs can become
‘‘uncoupled’’, resulting in the generation of O2
 and OH
instead of NO under certain conditions such as scarcity or
absence of the cofactor, tetrahydrobiopterin, and=or of the
substrate, L-arginine, as well as in the presence of oxidation of
the Zn2þ-thiolate center of NOS homodimer. NOS catalytic
activity becomes ‘‘uncoupled’’ when the coupling between the
reductase domain and L-arginine oxidation at the active site is
lost and electron transfer from NADPH through the flavins
(FAD and FMN) to O2 is not inhibited, resulting, in fact, in a
formation of O2
 and=or OH (212).
Cells may defend against excessive ROS by intracellular
antioxidants, including NO, and by the coordinated activity
of scavenging enzymes. In particular, O2
 is transformed into
H2O2 by superoxide dismutase (SOD) isoenzymes. However,
FIG. 1. Mitochondrial permeability
transition pore (mPTP) is believed to
be composed of the adenine nucleotide
translocase (ANT) in the inner mem-
brane, the voltage-dependent anion
channel (VDAC) of the outer mem-
brane, and cyclophilin D (Cyp-D) in
the matrix. Ca2þ overload occurring
during ischemia should bring mito-
chondria closer to the threshold at which
mPTP opening takes place, favoring the
occurrence of prolonged mPTP opening
during reperfusion, a phenomenon de-
scribed as mitochondrial priming. mPTP
opening hardly occurs during ischemia,
because it is strongly inhibited by aci-
dosis. mPTP opening during reperfusion
may be due to Ca2þ overload, which
may stimulate the interaction of Cyp-D
with other mPTP component(s), which
triggers permeability transition. In fact,
typically they open in reperfusion when Ca2þoverload, generation of reactive oxygen species (ROS), and pH normalization
occur. Their opening leads to cell death through the release of pro-apoptotic factors and via ROS-induced ROS release. The
dashed vertical line represents the passage from ischemia (low pH) to reperfusion (pH normalization).
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since in the presence of Fe2þ or Cu2þ, the H2O2 can be trans-
formed into OH, which may be more toxic than O2
 and
H2O2, an increase in toxicity can occur. Yet, O2
 itself may
trigger the release of Fe2þ from Fe3þ-complexes (Haber–Weiss
cycle). Therefore, O2
 can be directly and selectively delete-
rious and=or it can be deleterious via its transformation into
OH. As the flux of O2
 exceeds the one of NO, cellular
damage may develop induced by one-electron oxidations
caused by nitrogen dioxide and by the Fenton reaction (188).
O2
 can also be transformed into ONOO, whose cytotox-
icity can be reduced by the addition of NO via a secondary
reaction due to the antioxidant properties of NO and for-
mation of nitrosating species in this process (34, 52, 164). Yet
the threat of OH can be avoided by the fact that H2O2 can be
quickly reduced to water by several enzymes (catalase, glu-
tathione peroxidase, and peroxiredoxins). It can, then, be ar-
gued that during reperfusion a limited formation of H2O2
may be protective if NO is adequately formed or added to
reduce ONOO cytotoxicity, via a secondary reaction, thus
avoiding mPTP opening. This is in line with the observation
that strategies to increase NO bioavailability (e.g., by nitrite
infusion (157)) in reperfusion are very often protective (e.g.,
Refs. 169, 178–180) and is in line with the concept that when
properly regulated ROS=RNS are not purely destructive (52),
but rather engage an important cellular signaling function
(see below, Redox signaling by ROS and RNS).
Reduced availability of nitric oxide
It is well known that NO can modify proteins via different
chemical processes. Actually, NO exerts many of its physio-
logical effects via the formation of complex (or coordinating)
bonds with the transition metal ions of heme groups (94, 142,
198). This kind of reaction is the basis for the activation of
classical vasodilatation, through a pathway wherein NO
binds to soluble guanylate cyclase, thereby stimulating the
formation of cyclic GMP (cGMP) from GTP. Subsequently,
cGMP activates protein kinase G, whichmediates many of the
actions of NO. It has been reported that physiological levels
of NO inhibit mPTP opening with an IC50 of 11 nM (19). As
said, when under pathological conditions NO production is
not sufficient or it is supraphysiological this results in dele-
terious effects.
Clearly many of the pathological processes correlated to
reduced availability of NO are due to the reduction of cGMP-
dependent effects. However, nitration of tyrosine by RNS (not
to be confused with nitrosylation, see below) may also play a
role (34). In fact, as reported above, under pathological con-
ditions NO reacting with O2
 can be just enough to form
ONOO. Thus, peroxynitrite can react directly and irrevers-
ibly with proteins, lipids, and DNA, a result that is frequently
deleterious (21). For instance, ONOO irreversibly blocks the
mitochondrial respiratory chain (108, 119). In fact, ONOO
reacts with sulfhydryl groups and iron–sulfur clusters in re-
spiratory complexes, and induces nitration=oxidation of
MnSOD, further augmenting mitochondrial oxidative stress
in a vicious cycle (158).Yet, as said, when NO is sufficiently
produced, ONOO cytotoxicity can be reduced via a sec-
ondary reaction(164). NO deficiency can also cause vaso-
constriction and formation ofmicro-thrombi into the lumen of
the small vessels (1, 162, 169). These mechanisms, combined
with the adhesion of the leucocytes to the endothelium, in-
duced by ROS, can lead to the ‘‘no-reflow phenomenon’’ (1,
162). As a consequence, NO deficiency and free radicals
also have downstream effects, resulting in the initiation and
progression of a highly orchestrated acute inflammatory re-
sponse through the release of cytokines, activation of vascular
endothelial cells and leukocyteswith expression of cell surface
adhesion molecules. Upregulation of a program of pro-
inflammatory genes will contribute to the onset and mainte-
nance of post-ischemic inflammation (162, 163).
Ca2þ overload
In normoxia, Ca2þ acts at several levels within the mito-
chondria to stimulate ATP synthesis, and these organelles can
be considered a major player in Ca2þ buffering. In fact, to
generate a proton gradient across the inner membrane, Ca2þ
uptake occurs in mitochondria that utilize oxygen (38–41).
The cytosolic Ca2þ overload starts during ischemia and is
further increased during reperfusion. In fact, the oxidative
stress depresses Ca2þ regulatory mechanisms. Altered Ca2þ
handling during ischemia induces structural fragility and
excessive contractile activation upon reperfusion. The Ca2þ
overload also activates calcium-dependent proteases, which
could partially degrade contractile proteins. These effects are
the basis of a progressive increase of ventricular diastolic
pressure (hypercontracture), myocardial stunning, and con-
traction band necrosis (100, 151, 170). Ca2þ overload favors
the expression of proapoptotic elements from mitochondria
(208) and increases the cellular osmolarity, favoring explosive
swelling of cardiomyocytes. Ca2þ overload may also occur
within mitochondria where it is considered to be responsible
for the prolonged opening of mPTP, which is considered the
point of ‘‘no-return’’ leading to cell death (see below and Refs.
38–41, 66) Actually, mitochondrial Ca2þ overload can lead to
enhanced generation of ROS, prolonged mPTP opening,
rupture of the outer mitochondrial membranes (OMM) due to
swelling, and cytochrome c release, thus leading to cell death
(8, 32). The interplay between cytosolic Ca2þ and mitochon-
dria is analyzed in more detail in other reviews of this Forum
(14, 39, 84).
Mitochondrial permeability transition pore opening
The mPTP is a nonspecific megachannel of the mitochon-
drial membrane whose prolonged opening in the first few
minutes of myocardial reperfusion promotes cell death (4, 8,
30, 32, 58, 60, 64, 69–72, 105). We should, however, keep in
mind that mPTP opens and closes all the time and that a
transient increase in opening probability of the pores may be
involved in ROS-dependent cardioprotection by pre-
conditioning (72, 105).
mPTP has been proposed to be formed by adenine nucle-
otide translocase (ANT), the voltage-dependent anion chan-
nel (VDAC), and cyclophilin-D (Fig.1) (38–41). Besides being
themoment of ‘‘no-return’’ for cell death in reperfusion, mPTP
opening is also involved in heart failure development (17, 58,
127, 196). The oxidative opening of mPTP is central in re-
perfusion injury (for reviews, see 38- 41,158), and, as said, it
causes mitochondrial depolarization, loss of small molecular
weight substances from the matrix, and rupture of OMM (6,
32, 126, 196). However, experiments with transgenic mice in
each of the putative components of mPTP reached contro-
versial results. In fact, neither gene deletion nor knockdown of
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VDAC nor ANT prevents mPTP opening in response to mi-
tochondrial Ca2þ overload (6, 9, 27, 97, 126). The intriguing
possibility that cyclophilin-D has a role in regulating apo-
ptotic proteins in a manner that is independent of the mPTP
has been suggested (46). Nevertheless, in transgenic mice
sustained modulation of a mitochondrial function may alter
cardiac development and functions not related to the response
to acute ischemia. Pharmacological tools to study the roles of
mPTP in acute ischemia=reperfusion scenario are available,
and could be applied clinically as therapeutic agents for is-
chemic heart disease (57–60, 86). In fact, selective targeting of
drugs designed to modulate mitochondrial function and ge-
nomics for therapeutic benefit are made possible by recent
advances in mitochondrial biology (for reviews, see Refs. 22,
86). More details on the central role of mPTP opening in
protection and reperfusion injury are given by other reviews
in this Forum (14, 29, 39).
In summary, conditions occurring during ischemia and
reperfusion, such as Ca2þ overload, ROS, inorganic phos-
phate and mitochondrial depolarization favor prolonged
mPTP opening (Fig.1). These factors are counteracted by
physiological mPTP antagonists, such as increased mito-
chondrial membrane potential, low pH, magnesium ions,
ADP, and nitric oxide (14, 39, 84).
In reperfusion, cell death can occur by apoptosis,
oncosis=necrosis, and autophagy (see the following for ex-
tensive review on this topic (e.g., Refs. 122, 134, 181)). How-
ever, autophagy is not simply a destructive phenomenon, but
in certain conditions autophagy can be considered a protec-
tive mechanism against I=R injury (for reviews, see Refs.
62,155). Besides irreversible injury leading to cell death and
myocardial infarction, reperfusion injury of the heart is
characterized by reversible contractile dysfunction (stun-
ning), endothelial dysfunction, microvascular damage, and
reperfusion arrhythmias. All these deleterious events can be
prevented by both pre- and postconditioning (190).
Preconditioning and Postconditioning
In 1986, Murry et al. (123) reported that four 5min cir-
cumflex occlusions, each separated by 5min of reperfusion,
followed by a sustained 40min occlusion (index-ischemia)
dramatically attenuated I=R injury in the dog heart. This
phenomenon was named ischemic preconditioning (PreC). In
2003, Zhao et al. (207) reported that three episodes of 30 sec of
reperfusion=30 sec of ischemia performed immediately after
index-ischemia (60min coronary occlusion) in the dog heart
dramatically attenuated reperfusion injury. This phenomenon
was named postconditioning (PostC). The protective effects
observed with PostC are comparable to those observed with
the powerful PreC (109, 113, 207). In fact, PostC may reduce
apoptosis, necrosis, and endothelial dysfunction=activation,
thus leading to a reduced endothelia=leukocyte interaction and
to a reduced ROS inflammatory formation. A reduced inci-
dence of reperfusion arrhythmias has been also observed (56,
96, 125). Notable, already by 1994Grech andRamsdale (63) had
reported that intermittent reperfusion may restore sinus
rhythm. Whether PostC protects from myocardial stunning is
still controversial (148, 172). These protective effects are dis-
cussed in the review of Vinten–Johansen et al. (190).
PostC, first described in dogs, was subsequently demon-
strated in other species, and can also be recruited clinically in
human patients to reduce infarct size (59, 73, 86, 140, 176).
Notably in humans, PostC has long-term protective effects
(86). The infarct size reduction by ischemic PostC depends on
duration of the index-ischemia, on the number and duration
of the brief re-occlusions, and=or on the presence of co-
morbidities (81, 148, 174). Further studies should resolve the
difference in efficacy of PostC between experimental models
and human subjects with comorbidities and=or aging (40, 149,
155, 190).
Besides passive effects attributed to modification of he-
modynamics during PostC maneuvers, the cardioprotection
triggered by PostC is attributed to active effects that are me-
diated by several signaling pathways (77, 139–141, 144, 147,
191). The link between passive and active effects is not clear,
but during initial reperfusion PostC delays, the post-ischemic
recovery of intracellular pH, and the ability to trigger the
activation of biochemical pathways and to limit infarct
size might depend on this pH effect [see below and Inserte
et al. (84)]. Potentially, in these activated pathways, varia-
tions of protein structures=activities occur via different
post-translational modifications, namely phosphorylation,
dephosphorylation, O-linked glycosylation, S-nitrosylation,
and sulfhydration (see below, Modalities of cell signaling in
cardioprotection). In this review we will focus on these mech-
anisms of cardioprotection with emphasis to redox-signaling
to reduce reperfusion injury.
Before analyzing these mechanisms, it is necessary to re-
view a brief description of the main cardioprotective path-
ways involved in pre- and postconditioning, which have been
described in several recent publications (59, 68, 71, 140, 146,
201). Also in this Forum up-to-date, aspects of the pathways
involved in PostC are reported (e.g., 29, 70).
Cardioprotective Pathways
It is now thought that, after a triggering phase in pre-
ischemic period, the actual protection by PreC occurs in the
reperfusion rather than ischemic phase with the repopula-
tion of sensitized G-protein coupled receptor (GPCR) at the
beginning of myocardial reperfusion following the index-
ischemia. Thus, pre and postconditioning activate cardio-
protective pathways that are protective against reperfusion
injury. A schematic representation of these cardioprotective
signal transduction pathways is reported in Figure 2.
Both PreC and PostC engage GPCR and enzymes that
converge on the mPTP. However, subtle differences are
present in the pathways and in cell signaling at different times
and different species (14–16, 29, 70, 77, 173). GPCR agonists
include adenosine, bradykinin, and opioids, with a possible
sensitization of relevant receptors by prior ischemias. The
exact subtypes of adenosine, opioids, and bradykinin recep-
tors involved in triggering protection are still a matter of
controversy (29, 142). We have shown a role for endogenous
bradykinin in PostC via B2-bradykinin receptor activation
(141, 144, 200). A role for these receptors in PostC has been
confirmed in other models, including a knockout mice model
(142, 200). Receptor tyrosine kinases may also be involved,
possibly via the epidermal growth factor receptor transacti-
vation to activate PI3K=Akt. The activation of PKC can be
downstream of Akt or, especially in the triggering phase, can
be achieved via phospholipase signaling with adenosine re-
ceptor agonism (65, 73, 134, 201). For the aims of the current
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review, the involvement of tyrosine kinases is particularly
intriguing since these kinases are activated by low doses of
hydrogen peroxide limiting reperfusion injury (166).
Collectively three major pathways are recognized: the
cGMP=PKG-pathway, the Reperfusion Injury Salvage Ki-
nases (RISK) pathway and Survivor Activating Factor En-
hancement (SAFE) pathway (65–73, 102, 139–144, 147, 191,
206) (Fig.2). RISK includes the phosphorylation of Akt,
ERK1=2, p70S6K, and NOS. SAFE pathway includes JAK and
STAT-3 phosphorylation, and both pathways may converge
on mitochondria via GSK-3b, which is suggested to be among
the end-effectors for the cardioprotection by ischemic PostC
(70–72,185). Other proteins regulating apoptosis, such as
Bad=Bax, Bcl-2, and Pim-1, are also correlated with cardio-
protection via prevention of mPTP opening and reduction of
mitochondrial swelling. Overall, various protective mecha-
nisms seem to converge on mPTP (72, 142, 146). Contextually
other enzymatic (phosphorylation and O-linked glycosyla-
tion) and nonenzymatic (nitrosylation and sulfhydration) in-
tracellular signaling may involve multiple targets, which
converge on organelles, particularly mitochondria, which are
considered critical events leading to protection (26, 70, 139–
144, 167, 186). These pathways and intracellular signaling are
not mutually exclusive and are recruited by both pre- and
postconditioning to a different extent, depending on a pleth-
ora of factors. In this perspective it is particularly intriguing
that VDAC, constituent of the mPTP, may be also a target for
O-linked glycosylation (see below). Therefore, apart from
cGMP=PKG, RISK, and SAFE pathways, there are redox
mechanisms and events that may be considered alternative or
cooperative to the classical pathways. Of note, the importance
of RISK has been recently questioned, and its relevance in
larger mammals seems to be severely limited; from a trans-
lational point of view these animal models may be more
suitable (76, 131, 173). Concerns and controversies about the
possibilities of translating the results of animal experiments
into human clinical trials have recently been discussed by van
der Worp et al. (189). Nevertheless, preliminary clinical data
indicate that drugs targeting RISK may confer a benefit to
patients with acute myocardial infarction over and above that
provided by myocardial reperfusion alone (70), but they re-
main to be confirmed in large-scale clinical studies. These
features are also considered by Ivanes et al. (86) and by
Vinten–Johansen et al. (190) in the present Forum.
Interaction Between Redox Environment
and Cardioprotective Pathways
ROS=RNS with a signaling role are suggested to be formed
during three time points: during preconditioning-ischemia
and=or during reperfusion that follows the brief pre-
conditioning-ischemia, as well as in pre and postconditioning
during the initial part of reperfusion that follows the index-
ischemia (Fig. 3) (30, 73, 142).
The origin of these protective reactive species can be many,
including mitochondria, in which KþATP (mKATP) channels,
which are considered targets of protective cascades (14, 142,
161, 168, 201), may play a pivotal role. In fact, it has been
suggested that mKATP channel activation leads to alkaliniza-
tion of the mitochondrial matrix and generation of ROS=RNS
with a protective signaling role (33, 142, 168, 201). It has also
been suggested that NO donors activate mKATP channels in
rabbit ventricular myocytes and potentiate the protective ef-
fect of mKATP opener diazoxide (168). However, controversy
exists on the nature, existence, and opening of mKATP chan-
nels, which may also be a toxic process (33, 36). Nevertheless,
FIG. 2. Schematic representation of
cardioprotective pathways (Reperfusion
Injury Salvage Kinases (RISK) path-
way and Survivor Activating Factor
Enhancement (SAFE) pathway). Post-
translational modifications of proteins
occur both in the cytosol and in organ-
elles, particularly within mitochondria in
which specific targets are recognized.
ADE (adenosine), OP (opioids), TNFa
(tumor necrosis factor alpha), PLC
(phospholipase C), and PLD (phospholi-
pase D), BK (bradykinin), EGF (epider-
mal growth factor); other acronyms as in
the text. Persistent acidosis during early
reperfusion, activation of RISK and SAFE
pathways, and the activation of other cell
signaling lead to cardioprotection, where
the prevention of mPTP opening plays a
central role. Reactive oxygen and nitro-
gen species (ROS=RNS) with signaling
role may affect other cell signaling. Al-
though sulfhydration and glycosylation
may occur in reperfusion, they are not
reported in ischemic postconditioning.
STAT3 is a transcription factor and thus
nuclear effects are expected. Yet, it has
also direct effects on mitochondria (see
review by Hausenloy et al. (70) in this
Forum). For further explanation, see text.
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it has been suggested that besides channel phosphorylation,
mKATP can be opened by NO
 and derivative (nitrosylation)
as well as by sulfhydration (see below). Moreover, mito-
chondrial connexin-43 has also been implicated in ROS sig-
naling although its role is not completely defined (14–16). A
target of ROS in redox signaling is the PKC (possibly PKCe2);
in fact hearts can be preconditioned by simply infusing free
radicals into the coronary arteries and that protection can be
blocked by a PKC antagonist (184). Indeed, it has been re-
ported that ROS can activate PKC in vitro by reacting with
thiol groups associated with the zinc finger region of the
molecule (98). RNS-dependent activation of PKC, possibly via
redox-sensible nitrosylation process, has been also suggested
(161, 180). Actually, PreC via ROS=RNS formation leads to a
decreased intracellular reduced glutathione (GSH) pool,
which may stabilize S-nitrosothiol formation by attenuat-
ing GSH-mediated trans-=denitrosylation, thus potentiating
redox signaling and converting death-signal into survival-
signal (161, 167).
Although PKC plays a pivotal role in cardioprotection,
PKC location in the signaling cascade is unclear (69, 70). Yet
the regulation and role of PKC is still debated, with a possible
role for directly activated PKC, together with possible PKG-
dependent phosphorylation of mitochondrial PKCe, which in
turn inhibits mPTP opening via ROS signaling (57, 201).
Generation of ROS=RNS, distal to mKATP opening, may
also trigger activation of kinases additional to PKC, including
p38-MAPK and JAK=STAT (15, 70, 73, 201). The involvement
of p38-MAPK and JNK in preconditioning was also reported
for angiotensin-II and summarized in the recent review by
Daiber (33). Besides kinase activation, the increased phos-
phorylationmay also be the result of thewell-known inhibitor
effect of ROS on phosphatases (for review, see Ref. 24).
We and other authors have shown that ROS scavengers such
as N-acetyl-cysteine (NAC) and N-(2-mercaptopropionyl)-
glycine (MPG) given during the PostC maneuvers prevented
the protective effects (43, 142, 150, 186). These scavengers given
in the first fewminutes ofmyocardial reperfusion following the
index-ischemia also prevent PreC-protection (73). Variations of
the activity of endogenous antioxidant enzymes in early re-
perfusion may also play an important role in PostC protection
(150). Another mechanism in both pre- and postconditioning
involves the persistence of intracellular acidosis during early
reperfusion (30, 54, 73, 83, 86). In fact, while acidosis prevents
mPTP-opening, the reintroduction of O2 at the beginning of
reperfusion may allow ROS signaling to activate protective
cascades. These may also prevent the reactivation of mito-
chondrial enzymes able to produce massive quantity of ROS.
Of note, acidosis is also responsible of nonenzymatic NO
formation (213), which has been suggested to be involved in
PostC-triggering (142).
Ultimately, the mPTP-opening during early reperfusion is
inhibited by many of the above reported effects. In particular,
persistent acidosis during early reperfusion may play a piv-
otal role, contributing to the limitation of mPTP-opening
and additionally favoring enzymatic and=or nonenzymatic
mechanisms of protection. Therefore, it can be argued that
phosphorylative processes and=or other modalities of signal
transduction (e.g., S-nitrosylation, S-sulfhydration, and O-
linked glycosylation) are recruited by both pre- and post-
conditioning to a different extent to achieve protection via
mitochondrial salvage.
Importantly, the cardioprotection by pre- and post-
conditioning can be mimicked pharmacologically by the ad-
ministration of endogenous ligands, such as adenosine,
bradykinin, or opioids, and by agents that act on mitochon-
dria such as diazoxide (141, 142, 144). Particularly intriguing
is the protective role of cyclosporine A, an inhibitor of mPTP-
opening, which has recently been used in humans during
reperfusion as a PostC agent (59, 86). It is also of note that
redox-sensitive cardioprotective effects can be induced by
nitroglycerin (31, 44) and by nitrite infusion (157).
Modalities of Cell Signaling in Cardioprotection
Cellular signaling or signal transduction pathways repre-
sent a common property of viable cells, which include signals
starting from enzymes, cyclic nucleotides, calcium, and even
gases such as carbon monoxide, hydrogen sulfide (H2S),
and NO. Although protein phosphorylation is the most
widely studied form of signal transduction, as above men-
tioned, there are many other post-translational modifications
of proteins (e.g., acetylation, glycosylation, glutathionylation,
methylation, nitration, nitrosylation, and ubiquitylation) (35,
79, 88, 92). As said, some of these ‘‘additional’’ modalities of
signal transduction have been described in the ischemia=
reperfusion scenario and have already shown their impor-
tance in cardioprotection. Of course, these include redox
FIG. 3. Reactive oxygen and nitrogen
species (ROS=RNS) with signaling
role have been described during brief
preconditioning ischemia, during re-
perfusion following the brief pre-
conditioning ischemia, as well as during
early reperfusion which follows the in-
dex-ischemia, both in preconditioning
(PreC) and postconditioning (PostC).
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signaling inwhich ROS=RNSmodify proteins in ameaningful
way, including S-nitrosylation by NO and derivative.
S-sulfhydration by H2S is also gaining ground as a cellular
signaling process in cardioprotection. Other interesting
signaling systems that are still poorly understood are
O-linked glycosylation, which involves the linkage of beta-N-
acetylglucosamine through an oxygen atom to proteins at
their serine and threonine residues (23, 42, 105, 106, 130).
Theoretically, all these modalities are not limited to interac-
tions with specific enzymes but rather act to regulate an entire
pathway influencing each other. For instance, an enzyme can
be phosphorylated and=or nitrosylated in a specific and=or
different site(s) with consequent increase or decrease of its
specific activity. Despite this interplay, for clearness sake, in
the following part we will consider singularly the most rele-
vant cellular signaling in cardioprotection (i.e., those enzy-
matic-mediated: phosphorylation and O-linked glycosylation,
and those nonenzymatic-mediated: redox signaling, including
S-nitrosylation and S-sulfhydration). Whenever possible, in-
teractions among these signaling processes are outlined. Of
course, each of these processes has been extensively reviewed
elsewhere (21, 35, 79, 80, 87, 88, 90, 98, 180, 193); therefore here
they are briefly analyzed with particular attention to the
cardioprotective mechanisms.
Enzyme-Mediated Post-Translational Modifications
in Cardioprotection
Phosphorylation
The processes of phosphorylation of proteins as regulatory
modalities in the cell have been known since the early 1950s
(20). In ischemia=reperfusion and cardioprotection, a plethora
of kinases and phosphatases are involved (see above and Refs.
14, 29, 70, 190). Processes of phosphorylation=dephosphory-
lation occur on the cell membrane, in the cytosol, and in or-
ganelles (Fig. 4). In particular in the mitochondria, which are
considered the final target of cardioprotective pathways (14),
phosphorylation=dephosphorylation occurs on the external
face of the OMM, in the intermembrane mitochondrial space
(IMS), and in the mitochondrial inner membrane (MIM) and
matrix.
As said, RISK and SAFE pathways consider phosphory-
lative cascades outside mitochondria (70, 71, 102, 185).
Sphingosine-1-phosphate (S1P), which plays a pivotal role in
cytoskeletal rearrangement and apoptosis, also seems neces-
sary for successful preconditioning. Recently it has been
shown that sphingosine kinase-1, the key enzyme catalyzing
the formation of S1P, is critical for cardioprotection by PostC
(89). Apart from the phosphorylative events in the cell
membrane and cytosol, converging lines of evidence support
that pathways converge on mitochondria, where phosphor-
ylation has an impressive impact on cardioprotection.
Therefore, here we focus on phosphorylation within mito-
chondria in the cardioprotective scenario [The role of mito-
chondrial function in Pre and PostC is reviewed in other
articles of the present Forum (14, 39)].
On the external face of the OMM, there are several intra-
cellular receptors (scaffolds), which serve as sites for the
integration of signals for different processes (i.e., apoptosis,
cytoprotection, energetic demand, fission, and steroidogene-
sis) (175). Among scaffolds, we consider the PKA anchoring
proteins (199), and the PKC-interacting proteins (152) RICKs
and RACKs (i.e., the receptors for inactive=active kinases,
respectively) (118). For instance, both PKCd and PKCe mito-
chondrial translocation have been seen to be involved in is-
chemia=reperfusion injury and cardioprotection, respectively
(28). Studies with cardiomyocytes have shown that inhibitors
of the PKC–RACK interaction abolish cardioprotection
against ischemia=reperfusion (25) as well as the associated
phosphorylation of mitochondrial targets (132). PKCe trans-
locates to the mitochondria where it phosphorylates VDAC
with consequent inhibition of the mPTP (7, 73). Yet, mito-
chondrial PKCe was found in complexes with MAP kinases.
Formation of these complexes correlates with phosphoryla-
tion=inactivation of the pro-apoptotic protein BAD (8, 205).
PKA can also link to the OMM through one of the PKA an-
choring protein (D-AKAP1) (67). Aside from several isoforms
of PKC and PKA, other kinases that have been shown to un-
dergo translocation to the OMM include GSK-3b, Raf kinases,
and ERKs. In particular, ERK1=2 may associate with the
OMM in a complex with PKCe, though their substrates have
not been defined (8). It has also been suggested that signalo-
somes (scaffolded caveolins containing enzymes) triggered by
cardioprotective ligands converge on OMM to activate
mKATP and to prevent mPTP-opening (57).
In the IMS, principal targets for phosphorylation are
mainly involved in bioenergetics and apoptosis. These pro-
cesses are particularly relevant in cardioprotective mecha-
nisms. The majority of phosphorylation in the IMS appears to
be on tyrosine residues. Given their location, phosphorylation
of these tyrosines might be predicted to influence nucleotide
transport (104). For instance, phosphorylation of ANT (com-
ponent of mPTP) at its Tyr194 has been found in rat hearts
either pre- or postconditioned with isofluorane (51). Aside the
IMS-facing cavity of ANT, other important proteins of the IMS
have emerged as phosphoproteins, including cytochrome c,
FIG. 4. Proteins can be O-linked glycosylated (O-linked
glycosylation, O-GlcNAc) and=or phosphorylated, and
the adjacent O-GlcNAc and=or phosphorylation can influ-
ence the addition of either moiety. An increase in the
production of mitochondrial reactive oxygen species (ROS)
with signaling role may be accompanied by an increase
in O-GlcNAc. Uridine-diphospho-N-acetylglucosamine:
polypeptide b-N-acetylglucosaminyltransferase (OGT); N-
acetylglucosaminidase (OGA); Protein kinases (PKs); Protein
phosphatases (PPs). See text for further explanation.
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creatine kinase, and Ser 115=116 of subunit I, as well as sites
within matrix-facing subunits IV and Vb (50). In studies of
myocardial I=R injury, hypoxia reduced complex IV function
coincidentally with hyperphosphorylation (Ser, Thr, and Tyr
residues) of several subunits on complex IV, including sub-
unit 1. Complex IV activity could be rescued by PKA inhibi-
tors (74, 155).
In the MIM and matrix, proteins fall into several func-
tional categories, including energy metabolism=oxidative-
phosphorylation, lipid metabolism, and redox enzymes;
frequent targets are pyruvate dehydrogenase complex, bran-
ched chain dehydrogenase, F1F0ATPase, and complex I. In
the context of cardioprotection, pharmacological pre- and
postconditioning with either adenosine or diazoxide led to
phosphorylation of many mitochondrial proteins. Studies
suggested at least five phosphorylation sites on the b subunit
of the F1F0ATPase (94). Inhibition of F1F0ATPase activity may
be a feature of the preconditioned heart, thus reducing ATP
consumption by reverse mode of the enzyme (145). In the
MIM of subsarcolemmal mitochondria, the phosphorylated
portion of connexin-43, which plays an important role in ROS
formation, increases with ischemia and decreases with PostC
(16, 146). From proteomic studies it appears that there are
more mitochondrial phosphoproteins than previously
thought, particularly within the matrix and on the matrix-
facing proteins of the inner mitochondrial membrane (78,
136), further supporting that phosphorylative processes occur
within the mitochondria (57,142). Therefore, our better un-
derstanding of mitochondrial phosphorylation will also be of
benefit for a future better understanding of the cardiopro-
tective phenomena.
O-linked glycosylation (O-GlcNAcylation)
There are two basic types of glycosylation that occur
on either asparagines (N-linked) or serines and threo-
nines (O-linked) residue of proteins. Linkage of beta-N-
acetylglucosamine through an oxygen atom (O-linked)
to proteins appears to be the most relevant in cardioprotec-
tion. While phosphorylation is determined by a plethora
of enzymes, O-linked glycosylation is controlled by
two enzymes, a transferase that attaches the sugar group
(uridine-diphospho-N-acetylglucosamine:polypeptide b-N-
acetylglucosaminyltransferase, OGT) and a hexosaminidase
that removes it (beta-N-acetylglucosaminidase,OGA) (Fig. 4).
It has been observed that ROS may increase flux through the
hexosamine biosynthetic pathway, resulting in greater
O-GlcNacylation of proteins (101, 160).
On several proteins, O-GlcNAcylation and O-phosphate
alternatively occupy the same or adjacent sites (the ‘‘yin–yang
phenomenon’’), leading to the hypothesis that one function of
this sugar group is to transiently block phosphorylation (197).
Due to the importance of phosphorylation in cardiac protec-
tion, one can speculate that O-GlcNAcylation may interfere
with protection. However, Champattanachai et al. (23) dem-
onstrated in isolated neonatal rat ventricular myocytes that an
inhibitor of OGT markedly reduced O-GlcNAcylation levels
and exacerbated I=R injury. The authors suggested that in-
creased O-GlcNAcylation levels may attenuate I=R induced
Ca2þ overload and that activation of metabolic pathways
leading to an increase in O-GlcNAcylation levels is an en-
dogenous stress-activated response that improves cell sur-
vival. It has been shown that glutamine-induced protection of
isolated rat heart from I=R injury is mediated via increased
protein O-GlcNAcylation levels (107). In particular, 30-min
pretreatment with glutamine significantly improved cardiac
functional recovery and decreased cardiac troponin-I release
during reperfusion. This cardioprotection has been attributed
to elevated levels of O-GlcNAcylation on nucleo-cytoplasmic
proteins. Ngoh et al. (129) have shown in isolated cardio-
myocytes subjected to hypoxia=reoxygenation that elevated
expression of OGA reduced O-GlcNAcylation levels and
augmented post-hypoxic cell death. Yet, short interfering
RNA directed against OGA, as well as pharmacological in-
hibition of this hexosaminidase, significantly augmented
O-GlcNAcylation levels and reduced hypoxia=reoxygenation
cell death. Intriguingly, Ngoh et al. (129, 130) showed that the
mitochondrial VDAC is also a target for O-GlcNAcylation
modification and that the inhibition of OGA activity improves,
whereas augmentation impairs, mitochondrial membrane
potential recovery.
It should be emphasized that the interplay between these
two post-translational modifications of proteins is not always
reciprocal; rather a cross-talk between phosphorylation and
O-GlcNAcylation signaling exists. For example, some pro-
teins can be concomitantly O-GlcNAcylated and phosphory-
lated, and the adjacent O-GlcNAc or phosphorylation can
regulate the addition of either moiety (Fig. 4). Other
proteins, such as GSK-3b, have multiple and distinct phos-
phorylation=O-GlcNAcylation sites on the same protein. In-
terestingly, phosphorylation=inhibition of GSK-3b, which is
protective, increased O-GlcNAcylation of 10 proteins, but
decreased O-GlcNAcylation of 19 proteins (195). Conversely,
increasing global O-GlcNAcylation levels by OGA inhibition
resulted in a decrease in phosphorylation at about 33% of sites
and an increase in phosphorylation at about 18% of sites (194).
These studies clearly demonstrate nonreciprocal interplay
between O-GlcNAcylation and phosphorylation and indicate
the possibility for cooperativity between these types of cell
signaling.
A cross-talk between redox and O-GlcNAcylation signal-
ing has also been described (101). This may have a strong
relevance in cardioprotection; in fact an increase in mito-
chondrial ROS production may be accompanied by an in-
crease in O-GlcNAcylation (Fig. 4) (45), which, in turn, leads
to an increase in O-GlcNAcylation of mitochondrial proteins
and increased tolerance of mitochondria to stress. Some evi-
dence indicates a potential mitochondrial isoform of OGT (93,
128, 130, 131). Moreover, it has been reported that augmen-
tation of O-GlcNAcylation levels in cardiomyocytes attenu-
ates H2O2-induced loss of mitochondrial membrane potential
(23, 93, 128, 131) and that this may be due to O-GlcNAcylation
of mitochondrial proteins such as VDAC. All these studies
suggest that ROS from mitochondria contribute to the regu-
lation of O-GlcNAcylation of proteins, which could, in turn,
modulate the mitochondria response to oxidative-stress. Of
course to establish the real role of O-GlcNAcylation in the
contest of cardioprotection will require much more research.
For instance, though O-GlcNAcylation variations have been
observed in reperfusion, to the best of our knowledge, nobody
has studied the role of O-linked glycosylation in PostC. Fi-
nally, it must be pointed out that although acute O-GlcNA-
cylation is beneficial, chronic O-GlcNAcylation may promote
myocardial apoptosis (160).
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Nonenzymatic-Mediated Post-Translational
Modifications in Cardioprotection
Redox signaling by ROS and RNS
When properly regulated under physiological conditions,
both ROS and RNS are not purely destructive, but rather
engage in important signaling functions both in and outside
of mitochondria. Collectively with redox signaling, we con-
sider the fact that proteins may undergo reversible chemical
changes in response to changes in local redox potential. The
ROS-induced cellular responses include precise molecular
signals (modifications of cellular redox state) and their
transduction into the organelles and the nucleus (compart-
mentalization), which modifies their (patho)-physiological
role with a consequent influence on functions such as resis-
tance to stress, senescence, and programmed cell death.
Here we focus on the oxidative processes (oxidation) of
proteins, and in particular, on the modification of the cysteine
thiol by incorporation of a NO moiety to a sulfur atom to
form the S–NO bond (S-nitrosylation). Since it has been sug-
gested that nitric oxide is a weak S-nitrosating agent, it is
likely that to yield S-nitrosothiols an incorporation of NOþ
(nitrosyl cation) occurs. At high concentrations in oxygenated
solutions, NO may mediate S-nitrosylation via N2O3 forma-
tion by the autoxidation of NO to nitrogen dioxide radicals
and subsequent reactionwith anotherNO. The instantaneous
redox state and ultrastructural accessibility of cysteine resi-
due(s) under low-oxygen tension, such as hypoxia and is-
chemia, might determine whether a particular thiol in a given
protein is subjected to S-nitrosylation (167).
As said, low amounts of ROS generated during brief peri-
ods of ischemia=reperfusion or given in lieu of brief periods of
ischemia=reperfusion have been reported to be responsible
for preconditioning-triggering (48, 183, 184). The necessity of
ROS signaling was demonstrated by both inducing PreC with
ROS generators and avoiding PreC with ROS-scavengers
given before the index-ischemia. Also, many G-protein-
coupled receptor activators trigger preconditioning-like pro-
tection via ROS-dependent mechanisms, which may include
PKC activation (71, 73, 121, 122, 142, 198, 201, 202).
We were the first to consider that ROS could also be in-
cluded among the triggers of PostC. In fact, as said, large
spectrum ROS scavengers such as NAC and=or MPG given
during the PostC maneuvers prevented the protective effects
(43, 142, 147, 186). Yet, we have been unable to reproduce
cardioprotection with ROS generation by purine=xanthine
oxidase given at reperfusion (141). Since ROS scavengers,
given at the beginning of reperfusion, abolished both pre- and
postconditioning-induced protection (72, 141, 153, 186), it is
likely that the type, the concentration, and=or the compart-
mentalization of reactive species may play a pivotal role in
triggering protection at reperfusion time. We can not exclude
that a different ROS generator could trigger PostC protection
(142). Postconditioning increased cardiac 3-nitrotyrosine
concentration (a marker for ONOO- formation) after 5min of
reperfusion in normal but not in cholesterol-fed rats. Thus,
early increase in ONOO- after PostC may play a role in PostC-
protection (99). However, hyperlipidemia enhances pre-
ischemic levels of ONOO-(133), but alters the PostC-induced
ONOO- formation and blocks the protective effect (99). Fur-
thermore, Iliodromitis et al. (81) and Wang et al. (192) suggest
that PostC may reduce ONOO- formation. In particular, Ilio-
dromitis et al. (81) report that PostC reduces myocardial and
circulating levels of 3-nitrotyrosine after 10min of reperfusion
in the normal, but not in the hyperlipidemic rabbits. We have
shown in rat hearts that, after 7min of reperfusion, PostC
induces an increase in S-nitrosylation of proteins and a re-
duction in 3-nitrotyrosine levels (150). To reconcile these ap-
parent opposing results (81, 99, 150, 192)we can speculate that
after an initial increase in ONOO-, a further increase in NO
(via enzymatic and nonenzymatic processes (213)) can lead to
the formation of N2O3, thus lowering ONOO
- level and in-
creasing S-nitrosylation (see also below). In fact, a decrease in
ONOO- levels in the presence of excess NOmay be due to the
secondary chemical interactions occurring between NO and
ONOO- (164). Many different endogenous enzymes regulate
the intra-tissue homeostasis of ROS, including SOD and
catalase (142, and references therein). We found that PostC
discretely changes the activity of these enzymes in early re-
perfusion, decreasing SOD and increasing catalase activity
(150). These effects might shift reactions towards RNS for-
mation andmay have impact on S-nitrosylation thus reducing
injury due to oxidative-stress (see below and Figs. 5 and 6).
In this context, the sulfhydryl chemistry of cysteine resi-
dues within proteins represent peculiar targets, as they can
adopt multiple oxidation states (75). In fact, cysteines can
react with ROS=RNS to yield a number of species including
intra- and intermolecular disulfide bonds (disulfide cross-
linking), S-nitrosylated proteins, or the formation of mixed
disulfides with glutathione (glutathionylation) (Fig.5) (79, 87).
For instance, oxidation=nitrosylation=glutathionylation also
represents intra-mitochondrial redox signals. In fact, experi-
ments have shown that low concentrations of H2O2 and
S-nitroso-N-acetylpenicillamine cause redoxmodification of a
selected group of mitochondrial proteins, despite little change
FIG. 5. Chemical relationship among different reactive
oxygen species (ROS), reactive nitrogen species (RNS), and
hydrogen sulfide (H2S), and their impact on some post-
translational modification of proteins. The processes, the
enzyme activities, and the reactions increased by post-
conditioning (PostC) are in thick bold lines, those decreased by
PostC are in dashed=thin lines. In the excess of NO, the sec-
ondary reaction between ONOO- and NO may favor S-ni-
trosylation. H2S physiologically produced by CSE
from cysteine, induces S-sulfhydration of proteins. GSH,
glutathione; GSSG, glutathione disulfide; GSNO, S-
nitrosoglutathione. See text for further explanation and other
acronyms.
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in the redox status of the global mitochondrial thiol pool (79).
Several of these proteins were recognized as redox-modified
in response to endogenous mitochondrial ROS formation.
Proteins targeted included pyruvate-dehydrogenase-kinase-2
and propionyl-CoA-carboxylase, among others. Both en-
zymes were inhibited by oxidation and could be reactivated
by reduction with dithiothreitol (DTT). It can be inferred that,
though many mitochondrial proteins can be thiol-modified
under oxidative-stress, only a small subset of these modifi-
cations can be considered a real physiological=reversible re-
dox signal and that the primary distinction between them
would appear to be site-specific. In this context, S-nitrosyla-
tion and glutathionylation of proteins can be considered
pivotal signaling in cardioprotection. Due to space constraint,
we focus on S-nitrosylation. Useful information on the
molecular mechanisms and potential clinical significance of
S-glutathionylation can be found in the recent review by
Dalle–Donne et al. (35).
S-Nitrosylation
Nitric oxide can be generated by enzymatic and nonenzy-
matic processes (213). Incorporation of NO moieties by co-
valent bonding to protein groups is chemically possible in the
case of cysteine thiols, tryptophan indols, and amines (lysine
and N-terminal) (172, 204), although S-nitrosylation (i.e.,
the S–NO bond) can be considered the most important in
the ischemia=reperfusion scenario, because of its higher re-
activity, its occurrence in biological systems, and its influence
on many protein functions. In fact, S-nitrosylation has
emerged as an intriguing signaling modality, independently
of the induction of cGMP production by NO, effectively
acting as a reversible molecular switch analogous to phos-
phorylation. From a terminology viewpoint, the incorpora-
tion of NO=NOþmoiety to a thiol can be clearly individuated
because of the prefix ‘‘S-’’, referring to the incorporation of
the moiety to a sulfur atom to form the S–NO bond. The
term nitration, instead, describes the incorporation of nitro-
triatomic group (NO2) at position 3 of the phenolic ring of
tyrosine residues (Fig. 5). Although nitration may be a step of
protective pathways (99), thismodification is clearly related to
the formation of peroxynitrite in cardiovascular diseases (for
reviews, see Refs. 85, 139, 187).
Due to the complexity of NO and thiol chemistry, there
are many possible reaction mechanisms that can lead to S-
nitrosylation (Fig. 5), although which one prevails in vivo is
still debated (79, 204). Of course, a complete view of the role of
NO in cardioprotection must now include these cGMP-
independent=redox-dependent along with ‘‘classical’’ cGMP-
dependent mechanisms. Indeed, the role of NO in the
cardioprotection afforded by PreC (21, 92) and PostC (139,
142) has been well documented. Until recently, however,
many studies have centered on elucidating the role of classical
NO signaling through cGMP to the mitochondria (140). Re-
cently Sun et al. (178–180) have shown that PreC may cause
S-nitrosylation of proteins involved in Ca2þ handling and
energetics. Intriguingly, many of the proteins showing in-
creased S-nitrosylation with cardioprotection are mitochon-
drial proteins. It is likely that the high level of reactive
cysteines in mitochondrial proteins, and the increased stabil-
ity of N2O3 in the hydrophobic milieu of the mitochondria,
would favor S-nitrosylation (21). Interestingly, although
PostC and late-preconditioning both require NO, protein
S-nitrosylation has not been deeply examined under these
conditions. We have shown that PostC induces an increase in
S-nitrosylation of proteins, particularly low molecular weight
proteins (150). In a recent study, addition of a mitochondria-
targeted S-nitrosothiol at the beginning of reperfusion has
also been found to be cardioprotective against ischemia=
reperfusion injury (154). Sun et al. (179) also showed that
perfusion of hearts with GSNO improved left ventricular
function and protected against ischemia. Among others,
mitochondrial F1F0ATPase-a-subunit and a-ketoglutarate-
dehydrogenase were S-nitrosylated, and their activities were
inhibited and enhanced, respectively. As said above, these
results are in agreement with early studies, indicating that
PreC saves post-ischemic ATP consumption, and protects
against the loss of a-ketoglutarate activity (145, 201).
The cardioprotection by estrogen observed under condi-
tions of increased contractility has been shown to involve an
increase of S-nitrosylation of proteins. In fact, estrogen results
in upregulation of cardiac eNOS and nNOS, and several
S-nitrosylated proteins were identified, including the
a-ketoglutarate dehydrogenase, the F1F0ATPase-a-subunit,
the L-type calcium channel, and the cardiac sarcoplasmic re-
ticulum Ca2þ-ATPase, which reduces calcium loading during
ischemia and early reperfusion, thereby reducing I=R injury
(179). It has been suggested that atorvastatin- and sevo-
flurane-induced cardioprotection are mediated by increasing
S-nitrosylation of cyclooxygenase-2 and sarcolemmal pro-
teins, respectively (5, 18). Also the anti-apoptotic effect of NO
has been linked to the inhibition of caspase-3 activation
through cGMP-dependent and -independent mechanisms. In
particular, S-nitrosylation–denitrosylation of caspase-3 were
mechanisms by which Fas ligand was controlling the process
of apoptosis (95, 114).
S-nitrosylated proteins could elicit their regulatory effects
and protect cells by changing the structure and activity of
proteins (i.e., triggering signaling pathways), and=or pro-
tecting the modified cysteine residues from further irrevers-
ible modification under oxidative=nitrosative-stress, and=or
FIG. 6. Nitrosylation and glutathionylation are reversible
post-translational protein modification leading to protection;
oxidative=nitrosative stress may lead to irreversible modifi-
cations of protein which leads to damages. See also Figure 5.
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allowing the activity of these proteins=enzymes to be restored
more quickly during I=R (Fig. 6) (179). It should be noted that,
though nitrosylation and denitrosylation do not require en-
zymatic activities, they may be influenced by the presence of
enzymes, metals and, of course, NO sources, thus deter-
mining compartmentalization (13, 114, 117).
S-sulfhydration
Hydrogen sulfide is a gas that can be physiologically gen-
erated from L-cysteine by the action of two enzymes
cystathionine beta-synthase (CBS) and cystathionine gamma-
lyase (CSE). Hydrogen sulfide physiologically modifies
cysteines in a large number of proteins by S-sulfhydration,
converting P–SH groups to persulfide group (P–SSH) (124),
which thus appears to be another posttranslational modifi-
cation for proteins (Fig. 5). Similar to nitrosylation the cova-
lent modification in S-sulfhydration is reversed by
reducing agents, such as DTT (124, 193). In the last few years,
H2S has been implicated in the regulation of several (patho)-
physiological processes such as vasodilatation, cardio-
inotropism, and cardioprotection, to name just few. For
instance, in CSE–=– mice, vessels and the heart do not form
H2S and animals show endothelial-dysfunction and hyper-
tension (111); CSE inhibitors augment post-ischemic cardiac
damage and H2S donors are able to trigger cell signaling,
leading to cardioprotection (47, 111). Importantly, both en-
dogenous and exogenous H2S induce PostC-like cardiopro-
tection, involving theAkt–eNOS–PKCpathway.Moreover, the
PKC inhibitor chelerythrine and the KATP channel blockers,
glibenclamide or 5-hydroxydecanoate, are able to reverse the
cardioprotective effects of the H2S-donor, NaHS (89, 203).
While it is not clear whether and=or how H2S modifies the
activity of RISK=SAFE enzymes involved in PostC, it seems
that H2S directly alters the activity of KATP channels. In fact,
NaSH sulfhydrates the Kir6.1 subunit of KATP channels exog-
enously expressed in HEK293 cells. Treatment with DTT re-
verses the NaHS-mediated KATP sulfhydration (124).
Moreover, H2S interacts with Cys6 and Cys26 residues of the
extracellular N-terminal of SUR1 subunit of KATP channel
eterologhe complex. Direct chemical modification of SUR1
subunit protein may represent a molecular mechanism for the
activation of KATP channels by H2S (90). Yet at physiological
concentrations, H2S relaxes vascular tissues via the activation of
sarcolemmal KATP channels in smooth muscle cells (193). Also
the vasodilatation by garlic reflects H2S action on KATP chan-
nels (111). Nevertheless, we should keep in mind that a direct
KATP sulfhydration has not been demonstrated in the cardio-
protective context. Moreover, the molecular basis of mKATP
channels (in which cardioprotection seems more relevant than
the sarcolemmal channels) remains unclear at present. Finally,
it should be noted that cardiovascular KATP channels are gen-
erally thought to consist of Kir6.2=SUR2A subunits, in the case
of heart muscle, or Kir6.1=SUR2B subunits in smooth muscle
sarcolemma. However, there have been several reports of
Kir6.1 mRNA and protein expression in the hearts of human,
guinea pig, chick, rat, and mouse (103).
In the long run, the inducible form of heme oxygenase
(HO), HO-1, may play a key role in maintaining antioxidant
and oxidant homeostasis when cellular injury occurs (110).
Notably, the H2S donor, diallyl sulfide, induces the activation
of ERK, the expression and nuclear translocation of the tran-
scription factor Nrf2, and the activation of ho-1 gene. These
results suggest that H2S may play a role in prolonged pro-
tective effects by HO-1 overexpression (61). For additional
data on the physiological role of H2S, see reviews (111, 182).
Summary and Conclusions
Myocardial damage during reperfusion, among other
processes, can be due to oxidative stress, the cellular=mito-
chondrial Ca2þ overload, the reduced availability of NO, the
recovery of intracellular pH, and the consequent formation of
mPTP, leading to the massive liberation of ROS=RNS. The
NO deficiency can also favor vasoconstriction, formation of
micro-thrombi, adhesion of leucocytes to the endothelium,
leading to the ‘‘no-reflow phenomenon’’ (1, 162, 169).
Cardioprotection by ischemic pre- and postconditioning
shares some of the signal transduction pathways. In particu-
lar, both PreC and PostC studies suggest that early reperfu-
sion acidosis is necessary to avoidmPTP opening and to allow
ROS signaling (29, 30, 142). The protective cascades in early
reperfusion converge on mitochondria and in particular on
mPTP. In mitochondria, several proteins are phosphorylated.
Beside kinase phosphorylation, other modalities of cell sig-
naling are gaining ground. In particular, O-GlcNAcylation
modification, S-nitrosylation, and S-sulfhydration of proteins
are emerging as new signaling mechanisms that regulate cell
function and play critical roles in mediating the response of
cells to stress. It appears that when protein O- GlcNAcylation,
S-nitrosylation, and S-sulfhydration increase, I=R injury is
reduced, whereas when they decrease damage is exacerbated.
However, we must keep in mind that the interplay between
cell signalingmay influence the outcomes. Cross-talk between
different modalities of signaling may occur and may be the
basis of controversial observations. Therefore a better un-
derstanding of this crosstalk may contribute to solve the co-
nundrum relative to the role of RISK and=or SAFE pathway in
cardioprotection deriving from conflicting results obtained
with different models of pre- and postconditioning (14, 70,
131, 174, 190). It will be important to understand how post-
transitional modifications of different proteins are regulated
in the context of cardioprotection. For instance, it is likely that
S-nitrosylation of different protein controls does not solely vary
in function of the amount of NO. Data suggest that besides
kinases, phosphatates, antioxidant enzymes, and NOSs, other
enzymes such those involved in O-GlcNAcylation (OGA and
OGT) and=or in H2S synthesis (CBS and CSE) can modulate
post-ischemic cardiomyocyte survival. Subcellular localization
of enzymes may favor or contrast protein post-transitional
modifications and this likely contributes to the differences in
final outcome.
Mitochondria play a role of paramount importance in
ROS=RNS signaling and in cardioprotection and many of the
considered post-translational processes also occur in these
organelles. Understanding the compartmentalized subcellu-
lar signaling and crosstalk among them is the challenge re-
searchers should face in the future, to better fight
ischemia=reperfusion injury, especially in the presence of
other comorbidities and therapies.
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Abbreviations Used
Akt¼protein kinase B
ANT¼ adenine nucleotide translocase
CBS¼Cystathionine beta-synthase
cGMP¼ cyclic GMP
CSE¼ cystathionine gamma-lyase
DTT¼dithiothreitol
GPCR¼G-protein coupled receptor
GSK-3b¼ glycogen synthase kinase
H2O2¼hydrogen peroxide
I=R¼ ischemia=reperfusion
IMS¼mitochondrial intermembrane space
JAK¼ Janus activated kinase
MIM¼mitochondrial inner membrane
mKATP¼mitochondrial KþATP
MPG¼N-(2-mercaptopropionyl)-glycine
mPTP¼mitochondrial permeability transition
pore
NAC¼N-acetylcysteine
NO:¼nitric oxide
NOS¼nitric oxide synthase
O2
 ¼ superoxide anion
OGA¼O-GlcNac transferase
OH ¼hydroxyl radical
OMM¼ outer mitochondrial membrane
ONOO ¼peroxynitrite
P13K¼phosphatidylinositol 3-kinase
p70S6K¼P70s6 ribosomal protein S6 kinase
PKC¼protein kinase C
PKG¼protein kinase G
PostC¼postconditioning
PreC¼preconditioning
RACKs¼ receptors for active kinases
RICKs¼ receptors for inactive kinases
RISK¼ reperfusion injury salvage kinases
RNS¼ reactive nitrogen species
ROS¼ reactive oxygen species
S1P¼ sphingosine-1-phosphate
SAFE¼ survivor activating factor enhancement
SOD¼ superoxide dismutase
STAT3¼ signal transducer and activator of
transcription 3
VDAC¼voltage-dependent anion channel
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